Choosing the right biologic for severe asthma: precision medicine through the lens of patient-centered decision making.

[1]  M. Blaiss,et al.  Shared decision making for the allergist. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[2]  S. Szefler,et al.  Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: To biologic or not to biologic? , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[3]  J. Oppenheimer,et al.  Immunomodulators and Biologics: Beyond Stepped-Care Therapy. , 2019, Clinics in chest medicine.

[4]  W. Busse,et al.  Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. , 2013, American journal of respiratory and critical care medicine.

[5]  J. Oppenheimer,et al.  Asthma biologics: Underuse, overuse, and best use? , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[6]  R. Sehmi,et al.  Weight‐adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed‐Dose Subcutaneous Mepolizumab , 2018, American journal of respiratory and critical care medicine.